Colorectal Cancer

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Cathy Eng, MD, FACP, FASCO, discusses the role of ​preventive screening in colorectal cancer.

Michael J. Cavnar, MD, discusses the roles of chemotherapy and surgery in metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

Michael J. Cavnar, MD, discusses the importance of multidisciplinary care in colorectal cancer.

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Michael J. Cavnar, MD, discusses the management of patients with liver metastas​es in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

The United States Preventive Services Task Force now recommends that colorectal cancer screening begin 5 years earlier, at age 45 versus age 50, according to new draft guidelines.

Nilofer S​aba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.

The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.

Immunoscore®, a host immune response classification tool, has demonstrated the ability to significantly affect treatment decision-making for patients with stage II colon cancer, particularly among those with high-risk disease.

The artificial intelligence–powered platform Clinical Trial Finder, which stemmed from a collaboration between the Colorectal Cancer Alliance and the digital health company TrialJectory, could prove beneficial for younger patients with colorectal cancer and for those who are being treated at community cancer centers.

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.